Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States

INTRODUCTION: Clinical trials have shown brodalumab to have better efficacy than ustekinumab for the treatment of moderate-to-severe psoriasis. An estimation of the cost-effectiveness of brodalumab vs. ustekinumab is warranted and may be useful for treatment decision-making processes, especially in...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Steven R., Rastogi, Shipra, Lin, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109035/
https://www.ncbi.nlm.nih.gov/pubmed/30006866
http://dx.doi.org/10.1007/s13555-018-0251-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109035/
https://www.ncbi.nlm.nih.gov/pubmed/30006866
http://dx.doi.org/10.1007/s13555-018-0251-4

Ejemplares similares